- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00562445
Adrenal Insufficiency in Critical Emergencies in Digestive Diseases
Evaluation of the Incidence and Relevance of the Adrenal Insufficiency in Critical Emergencies in Digestive Diseases (GI Bleeding and Acute Pancreatitis)
Observational study about the incidence of relative adrenal insufficiency in patients with cirrhosis and acute variceal bleeding; in patients with acute peptic gastrointestinal bleeding and without liver disease; and in patients with severe acute pancreatitis.
This is a study using pharmaceutical specialties in the approved conditions of use.
Study Overview
Status
Detailed Description
Observational, prospective, open-label, in-patient study, that includes patients with upper gastrointestinal bleeding of variceal or peptic origin, and in patients with severe acute pancreatitis.
The adrenal function of every patient included will be evaluated in the first 24 hours of admission This assessment shall be performed using the corticotropin-stimulation short test (synacthen test), that includes serum and saliva determination of cortisol, in basal conditions and 30 and 60 minutes after the administration of 250 ug of corticotropin synthetic (Synacthen, Novartis Pharma AG, Basel, Switzerland).
The cortisol levels will be determined by competitive immunoassay using direct chemoluminescence technology (Bayer Corporation, Pittsburgh, PA, USA).
In patients with severe acute pancreatitis all of these determinations will be repeated at the third day of admission.
Several other clinical and biochemical features will be recorded.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Candid Villanueva, MD
- Phone Number: +34620955006
- Email: cvillanueva@santpau.es
Study Locations
-
-
-
Barcelona, Spain, 08025
- Recruiting
- HospitalSCSP
-
Contact:
- Candid Villanueva, MD
- Phone Number: +34620955006
- Email: cvillanueva@sanrpau.es
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria (one of the following):
- Presence of acute upper gastrointestinal bleeding (variceal or peptic) + presence of hypovolemic shock (defined as a systolic blood pressure <100 mmHg coupled with a heart rate> 100 ppm), or Hb < 80 g / L;
- Acute pancreatitis (diagnosed by clinical, radiological and biochemical features)with severity criteria (At least one of the following: index of Ranson > 3, APACHE II > 8 or CPR> 120 mg/L, Balthazar CT grade E)
Exclusion Criteria:
- Age <18 years and >80 years.
- Pregnancy.
- Patient refusal to participate in the study.
- Prior corticosteroids treatment(oral or topical).
- Treatment during the 30 days prior to inclusion with any of the following drugs: contraception, etomidate, ketoconazole, rifampin or phenytoin.
- History of cranial trauma or surgery.
- Any malignancy in treatment or progression.
- HIV infection.
- Prior known adrenal pathology.
- Patients not eligible to any active treatment because the existence of any clinical condition considered terminal.
- Patients with associated traumatic blood loss, or any other extraintestinal source of active bleeding.
- Burns.
- Patients who have been previously included in this study.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
1
Peptic bleeding
|
2
Portal hypertension bleeding
|
3
Severe acute pancreatitis
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Relative adrenal insufficiency
Time Frame: 1 week
|
1 week
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Therapeutic failure
Time Frame: 45 days
|
45 days
|
Survival
Time Frame: 45 days
|
45 days
|
Variations in portal hypertension.
Time Frame: 7 days
|
7 days
|
Need for vasopressive drugs
Time Frame: 45 days
|
45 days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Candid Villanueva, MD, Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Study record dates
Study Major Dates
Study Start
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ISRRA-HDA2007
- EudraCT: 2007-002355-16
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Pancreatitis
-
Centre Hospitalier Universitaire de NiceRecruiting
-
John Gasdal KarstensenCompleted
-
Tianjin Nankai HospitalCompletedAcute PancreatitisChina
-
Mayo ClinicNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedAcute Pancreatitis (AP) | Gallstone Pancreatitis | Alcoholic Pancreatitis | Trauma Acute Pancreatitis | Hypertriglyceridemia Acute Pancreatitis | Idiopathic (Unknown) Acute Pancreatitis | Medication Induced Acute Pancreatitis | Cancer Acute Pancreatitis | Miscellaneous (i.e. Acute on Chronic Pancreatitis)United States
-
Northern State Medical UniversityCompleted
-
Erzhen ChenRenJi HospitalUnknownPancreatitis,Acute NecrotizingChina
-
Orlando Health, Inc.Mayo Clinic; University of Alabama at Birmingham; University of Southern California and other collaboratorsActive, not recruitingPancreatitis,Acute NecrotizingUnited States
-
University of OuluCopenhagen University Hospital, HvidovreUnknownAcute Necrotizing PancreatitisFinland
-
Sichuan Academy of Medical SciencesPeking Union Medical College HospitalCompleted
-
Interscope, Inc.CompletedAcute Pancreatitis | Necrotizing Pancreatitis | Acute Pancreatic NecrosisUnited States, Netherlands, Germany